Literature DB >> 15820209

MMP-9 regulates both positively and negatively collagen gel contraction: a nonproteolytic function of MMP-9.

Olivier D Defawe1, Richard D Kenagy, Chun Choi, Samuel Y C Wan, Christophe Deroanne, Betty Nusgens, Natzi Sakalihasan, Alain Colige, Alexander W Clowes.   

Abstract

OBJECTIVE: Constrictive remodeling accounts for lumen loss in postangioplasty restenosis. Matrix metalloproteinase-9 (MMP-9) has been shown to prevent constrictive remodeling in vivo. To investigate potential mechanisms for this observation, we investigated the role of MMP-9 in smooth muscle cell (SMC)-mediated collagen gel contraction, an in vitro model of constrictive remodeling.
METHODS: Fischer rat SMCs were stably transfected with a construct-expressing rat-MMP-9 under the control of a tetracycline (Tet)-off promoter. SMCs were seeded in type I collagen gels (2.4 mg/ml) in the presence or not of tetracycline (1 microg/ml), and gel contraction was defined as the percentage of retraction of the collagen gel. The depletion of MMP-9 was obtained by using siRNA targeting MMP-9 mRNA or a blocking antibody.
RESULTS: Gel contraction was significantly reduced at all times when MMP-9 was overexpressed (Tet-) as compared with the control condition (Tet+). However, MMP-9 depletion of control (Tet+) SMCs (using siRNA or antibody) also inhibited gel contraction. To resolve the apparent discrepancy and determine if MMP-9 exerts a dose-dependent biphasic effect on gel contraction, conditioned medium and purified rat-MMP-9 were prepared. Gel contraction was significantly increased by addition of 0.8 ng/ml of MMP-9, while high concentrations of MMP-9 (> or =100 ng/ml) inhibited contraction. The addition of BB94 and TIMP-1 did not alter the inhibitory or stimulatory effect of MMP-9.
CONCLUSIONS: Our data suggest that MMP-9, independent of its proteolytic function, has a biphasic effect on SMC-mediated collagen gel contraction. Understanding the different roles of MMP-9 should allow the development of better therapeutic strategies for restenotic vascular disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15820209      PMCID: PMC1381982          DOI: 10.1016/j.cardiores.2004.11.025

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  44 in total

1.  Increased MMP-9 activity in acute carotid plaques: therapeutic avenues to prevent stroke.

Authors:  I M Loftus; S Goodall; M Crowther; L Jones; P R Bell; A R Naylor; M M Thompson
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

Review 2.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

3.  The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism.

Authors:  E Hahn-Dantona; J F Ruiz; P Bornstein; D K Strickland
Journal:  J Biol Chem       Date:  2001-02-02       Impact factor: 5.157

4.  Low density lipoprotein receptor-related protein (LRP) is required for lactoferrin-enhanced collagen gel contractile activity of human fibroblasts.

Authors:  Yoshiharu Takayama; Hitomi Takahashi; Koko Mizumachi; Toshiaki Takezawa
Journal:  J Biol Chem       Date:  2003-04-01       Impact factor: 5.157

5.  Hyaluronan enhances contraction of collagen by smooth muscle cells and adventitial fibroblasts: Role of CD44 and implications for constrictive remodeling.

Authors:  J A Travis; M G Hughes; J M Wong; W D Wagner; R L Geary
Journal:  Circ Res       Date:  2001-01-19       Impact factor: 17.367

Review 6.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

7.  Dose-dependent limitation of arterial enlargement by the matrix metalloproteinase inhibitor RS-113,456.

Authors:  J K Karwowski; A Markezich; J Whitson; T A Abbruzzese; C K Zarins; R L Dalman
Journal:  J Surg Res       Date:  1999-11       Impact factor: 2.192

8.  Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction.

Authors:  Taher Nassar; Abdullah Haj-Yehia; Sa'ed Akkawi; Alice Kuo; Khalil Bdeir; Andrew Mazar; Douglas B Cines; Abd Al-Roof Higazi
Journal:  J Biol Chem       Date:  2002-08-08       Impact factor: 5.157

9.  Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion.

Authors:  Q Yu; I Stamenkovic
Journal:  Genes Dev       Date:  1999-01-01       Impact factor: 11.361

10.  Compensatory vascular remodeling during atherosclerotic lesion growth depends on matrix metalloproteinase-9 activity.

Authors:  Susan M Lessner; Deborah E Martinson; Zorina S Galis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-08-12       Impact factor: 8.311

View more
  12 in total

1.  Cdc42 regulates extracellular matrix remodeling in three dimensions.

Authors:  Nisha S Sipes; Yuxin Feng; Fukun Guo; Hyung-Ok Lee; Fu-Sheng Chou; Jonathan Cheng; James Mulloy; Yi Zheng
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

2.  ZIPK is critical for the motility and contractility of VSMCs through the regulation of nonmuscle myosin II isoforms.

Authors:  Satoshi Komatsu; Mitsuo Ikebe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-14       Impact factor: 4.733

3.  Matrix metalloproteinases 2 and 9 are elevated in human preterm laboring uterine myometrium and exacerbate uterine contractility†.

Authors:  Craig C Ulrich; Veronica Arinze; Carolina Bueno Wandscheer; Christian Copley Salem; Camellia Nabati; Neda Etezadi-Amoli; Heather R Burkin
Journal:  Biol Reprod       Date:  2019-06-01       Impact factor: 4.285

4.  Characterization of the natural history of extracellular matrix production in tissue-engineered vascular grafts during neovessel formation.

Authors:  Yuji Naito; Misty Williams-Fritze; Daniel R Duncan; Spencer N Church; Narutoshi Hibino; Joseph A Madri; Jay D Humphrey; Toshiharu Shinoka; Christopher K Breuer
Journal:  Cells Tissues Organs       Date:  2011-10-12       Impact factor: 2.481

5.  Transforming growth factor beta induces rosettes of podosomes in primary aortic endothelial cells.

Authors:  Christine Varon; Florence Tatin; Violaine Moreau; Ellen Van Obberghen-Schilling; Samantha Fernandez-Sauze; Edith Reuzeau; Ijsbrand Kramer; Elisabeth Génot
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

6.  Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices.

Authors:  Christopher Franco; Bernard Ho; Diane Mulholland; Guangpei Hou; Muzharul Islam; Katey Donaldson; Michelle Patricia Bendeck
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

7.  Characterization of total and active matrix metalloproteinases-1, -3, and -13 synthesized and secreted by anterior cruciate ligament fibroblasts in three-dimensional collagen gels.

Authors:  Erik Attia; Krista Bohnert; Haydee Brown; Madhu Bhargava; Jo A Hannafin
Journal:  Tissue Eng Part A       Date:  2013-10-25       Impact factor: 3.845

Review 8.  In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer.

Authors:  Bo Ri Seo; Peter DelNero; Claudia Fischbach
Journal:  Adv Drug Deliv Rev       Date:  2013-12-02       Impact factor: 15.470

9.  Matrix Metalloproteinases -14, -9 and -2 are Localized to the Podosome and Involved in Podosome Development in the A7r5 Smooth Muscle Cell.

Authors:  S E Thatcher; J E Black; H Tanaka; K Kohama; M E Fultz; L A Cassis; G L Wright
Journal:  J Cardiobiol       Date:  2017-05-10

10.  The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis.

Authors:  Lisa Cm Dahl; Zeyad Nasa; JieYu Chung; Be'eri Niego; Volga Tarlac; Heidi Ho; Adam Galle; Steven Petratos; Jae Young Lee; Frank Alderuccio; Robert L Medcalf
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.